Evidence map›Paper›PMID 42417963›Full record

ArticleCVIR endovascular2026

Sequential dual-dilution N-butyl cyanoacrylate embolisation ("Nitoryu" technique) for controlled distal penetration and proximal occlusion.

Yi-Wei Wu

Abstract read
In one paragraph

Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yi-Wei WuDepartment of Diagnostic Radiology, Tan Tock Seng Hospital, 11 Jln Tan Tock, Singapore, 308433, Singapore. wuyiwei753@gmail.com.ORCID http://orcid.org/0000-0003-4168-5205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN-butyl cyanoacrylate (NBCA) embolisation is an effective technique for rapid haemostasis and tumour devascularisation. However, selection of a single glue dilution requires balancing distal penetration against proximal control, often relying heavily on operator experience. Achieving both deep distribution and stable proximal occlusion can be challenging, particularly in complex lesions. TECHNIQUE AND CASE PRESENTATION: We describe a sequential dual-dilution NBCA embolisation technique ("Nitoryu" technique), in which a dilute NBCA-lipiodol mixture is first administered to achieve flow-directed distal penetration, followed by injection of a more concentrated mixture to achieve rapid proximal occlusion and stabilisation of the embolic cast. The technique was applied in two cases. In a patient with ruptured hepatocellular carcinoma and coagulopathy, multiple small tumour-feeding arteries and a poorly visualised culprit pseudoaneurysm required deep penetration of dilute glue, followed by proximal occlusion to ensure durable haemostasis. In a second case of bronchial artery pseudoaneurysm causing haemoptysis, a tiny tortuous feeder necessitated very dilute glue for distal delivery, while subsequent proximal embolisation with a more concentrated mixture reduced the risk of reflux and non-target embolisation. In both cases, the sequential approach allowed controlled embolisation with effective distal penetration of glue and stable proximal occlusion.

conclusionThe sequential dual-dilution NBCA embolisation (Nitoryu technique) enables controlled distal penetration and proximal stabilisation, and may improve safety and efficacy in selected cases requiring precise glue delivery.

Indexed as

Bronchial artery embolisationGlue embolisationHepatocellular carcinomaN-butyl cyanoacrylatePseudoaneurysmTransarterial embolisation

Identifiers

PMID42417963
PMCPMC13346415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.